CO6670529A2 - Sistema de suministro de buprenorfina de liberación sostenida - Google Patents
Sistema de suministro de buprenorfina de liberación sostenidaInfo
- Publication number
- CO6670529A2 CO6670529A2 CO13001795A CO13001795A CO6670529A2 CO 6670529 A2 CO6670529 A2 CO 6670529A2 CO 13001795 A CO13001795 A CO 13001795A CO 13001795 A CO13001795 A CO 13001795A CO 6670529 A2 CO6670529 A2 CO 6670529A2
- Authority
- CO
- Colombia
- Prior art keywords
- sustained release
- buprenorphine
- delivery system
- release system
- metabolite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1009549.5A GB2481018B (en) | 2010-06-08 | 2010-06-08 | Injectable flowable composition comprising buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6670529A2 true CO6670529A2 (es) | 2013-05-15 |
Family
ID=42471306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13001795A CO6670529A2 (es) | 2010-06-08 | 2013-01-04 | Sistema de suministro de buprenorfina de liberación sostenida |
Country Status (32)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| WO2013126552A1 (en) * | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| JP6279547B2 (ja) | 2012-04-17 | 2018-02-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| IL296882A (en) * | 2012-07-26 | 2022-12-01 | Camurus Ab | Opioid formulations |
| KR102098980B1 (ko) | 2012-07-26 | 2020-04-08 | 카무러스 에이비 | 오피오이드 제형 |
| EP2931253A1 (en) * | 2012-12-13 | 2015-10-21 | Heron Therapeutics, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9393211B2 (en) * | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| WO2014143635A1 (en) * | 2013-03-15 | 2014-09-18 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3509601A1 (en) | 2014-04-21 | 2019-07-17 | Heron Therapeutics, Inc. | A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam |
| HUE052224T2 (hu) * | 2014-04-21 | 2021-04-28 | Heron Therapeutics Inc | Poliortoészterbõl és szerves sav segédanyagból álló készítmények |
| US9801945B2 (en) | 2014-04-21 | 2017-10-31 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| CA2946281C (en) | 2014-04-21 | 2022-12-13 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| CN106470999B (zh) | 2014-04-28 | 2018-11-13 | 奥佛麦德公司 | 叔丁啡二聚体及其在治疗肠胃失调中的应用 |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| WO2016071767A1 (en) * | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US10786515B2 (en) | 2015-08-03 | 2020-09-29 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| FI3377041T3 (fi) | 2015-11-16 | 2023-11-30 | Medincell S A | Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen |
| CA3033046C (en) * | 2016-09-13 | 2021-09-07 | Alar Pharmaceuticals Inc. | Sustained-release buprenorphine formulations |
| EP3638240A2 (en) | 2017-06-16 | 2020-04-22 | Indivior UK Limited | Methods to treat opioid use disorder |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| AU2019209416A1 (en) | 2018-01-22 | 2020-07-30 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition for sustained release delivery of buprenorphine |
| AR117426A1 (es) * | 2018-05-11 | 2021-08-04 | Alar Pharmaceuticals Inc | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina |
| EP3863712A4 (en) | 2018-10-11 | 2022-07-20 | Indivior UK Limited | Buprenorphine to treat respiratory depression |
| US12403291B2 (en) | 2019-08-30 | 2025-09-02 | Intersect Ent, Inc. | Submucosal bioresorbable drug eluting platform |
| CN118831057A (zh) * | 2023-04-25 | 2024-10-25 | 深圳善康医药科技股份有限公司 | 丁丙诺啡植入剂及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE69534780T2 (de) | 1994-04-08 | 2006-10-05 | Qlt Usa Inc., Fort Collins | Flüssige Zusammensetzungen zur Arzneistoffabgabe |
| US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| SI2561860T1 (en) * | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| US7368126B2 (en) * | 2002-11-06 | 2008-05-06 | Guohua Chen | Controlled release depot formulations |
| JP2007525429A (ja) * | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー，インコーポレイテッド． | 細胞スケジュール依存性抗癌剤のための処方 |
| JP2008520547A (ja) * | 2004-10-04 | 2008-06-19 | キューエルティー ユーエスエー，インコーポレイテッド． | 眼部送達のためのポリマー送達処方 |
| AU2005304435B8 (en) * | 2004-11-10 | 2011-06-23 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
| HUE025842T2 (en) | 2007-02-15 | 2016-04-28 | Tolmar Therapeutics Inc | Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2010
- 2010-06-08 GB GB1413064.5A patent/GB2513267B/en active Active
- 2010-06-08 GB GB1009549.5A patent/GB2481018B/en active Active
-
2011
- 2011-06-06 NZ NZ604026A patent/NZ604026A/en unknown
- 2011-06-06 WO PCT/GB2011/051057 patent/WO2011154724A2/en not_active Ceased
- 2011-06-06 JP JP2013513755A patent/JP5986072B2/ja not_active Expired - Fee Related
- 2011-06-06 US US13/703,013 patent/US8921387B2/en active Active
- 2011-06-06 EP EP17205986.7A patent/EP3360538B1/en active Active
- 2011-06-06 PT PT117280370T patent/PT2579874T/pt unknown
- 2011-06-06 NO NO11728037A patent/NO2579874T3/no unknown
- 2011-06-06 BR BR112012031290A patent/BR112012031290A2/pt not_active Application Discontinuation
- 2011-06-06 FI FIEP17205986.7T patent/FI3360538T3/fi active
- 2011-06-06 KR KR1020127032282A patent/KR101865689B1/ko not_active Expired - Fee Related
- 2011-06-06 SI SI201131401T patent/SI2579874T1/en unknown
- 2011-06-06 SG SG2012089652A patent/SG186200A1/en unknown
- 2011-06-06 MY MYPI2012005274A patent/MY171625A/en unknown
- 2011-06-06 MX MX2012014335A patent/MX339209B/es active IP Right Grant
- 2011-06-06 EP EP23150636.1A patent/EP4218720A1/en active Pending
- 2011-06-06 EP EP11728037.0A patent/EP2579874B1/en active Active
- 2011-06-06 HR HRP20180118TT patent/HRP20180118T1/hr unknown
- 2011-06-06 PL PL11728037T patent/PL2579874T3/pl unknown
- 2011-06-06 LT LTEP11728037.0T patent/LT2579874T/lt unknown
- 2011-06-06 RU RU2012157244A patent/RU2607498C2/ru not_active IP Right Cessation
- 2011-06-06 HU HUE11728037A patent/HUE038275T2/hu unknown
- 2011-06-06 CA CA2801676A patent/CA2801676C/en active Active
- 2011-06-06 ES ES11728037.0T patent/ES2656938T3/es active Active
- 2011-06-06 RS RS20180068A patent/RS56820B1/sr unknown
- 2011-06-06 DK DK11728037.0T patent/DK2579874T3/da active
- 2011-06-06 AU AU2011263478A patent/AU2011263478B2/en active Active
- 2011-06-06 SM SM20180038T patent/SMT201800038T1/it unknown
- 2011-06-06 CN CN201180039223.3A patent/CN103079544B/zh not_active Expired - Fee Related
- 2011-06-06 ES ES17205986T patent/ES2939612T3/es active Active
- 2011-06-06 DK DK17205986.7T patent/DK3360538T3/da active
-
2012
- 2012-12-06 IL IL223488A patent/IL223488A/en active IP Right Grant
- 2012-12-06 ZA ZA2012/09233A patent/ZA201209233B/en unknown
- 2012-12-07 CL CL2012003462A patent/CL2012003462A1/es unknown
-
2013
- 2013-01-04 CO CO13001795A patent/CO6670529A2/es unknown
-
2016
- 2016-06-01 JP JP2016110259A patent/JP6251774B2/ja active Active
-
2017
- 2017-09-11 IL IL254417A patent/IL254417A0/en unknown
-
2018
- 2018-01-24 CY CY181100098T patent/CY1120761T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6670529A2 (es) | Sistema de suministro de buprenorfina de liberación sostenida | |
| BR112012031288A2 (pt) | composições | |
| ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| CR20110110A (es) | Composicion farmaceutica | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| PH12012501622A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
| MX2014008020A (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| WO2011140232A3 (en) | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents | |
| CL2011001768A1 (es) | Compuestos derivados de ciclopentanodiona; procesos para la preparacion de dichos compuestos; composicion herbicida; metodo para el control de pastos y malezas en cultivos de plantas utiles; y compuesto intermediario. | |
| MX2012003324A (es) | Compuesto de glicina. | |
| WO2011017054A3 (en) | Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| BRPI0920042A2 (pt) | uso de um composto, dispositivo médico implantável, método para a sua fabricação, e, método in vitro para exterminar, inibir ou prevenir o crescimento de um biofilme microbiano. | |
| CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
| EP2666773A8 (en) | Organic amine salts of azilsartan, preparation method and use thereof | |
| BRPI0920251A2 (pt) | composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. | |
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto | |
| MX2013006564A (es) | Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico. | |
| EP2692723A8 (en) | Aryloxy dihalopropenyl ether compound and use thereof |